Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ryan M. Finnegan"'
Autor:
Ryan M. Finnegan, Ahmed M. Elshazly, Nipa H. Patel, Liliya Tyutyunyk-Massey, Tammy H. Tran, Vishnu Kumarasamy, Erik S. Knudsen, David A. Gewirtz
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
Anti-estrogens or aromatase inhibitors in combination with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are the current standard of care for estrogen receptor-positive (ER+) Her-2 negative metastatic breast cancer. Although these combination t
Externí odkaz:
https://doaj.org/article/894a189ccef24ff08e4d0a659547be7f
Publikováno v:
Cancers. 14(17)
While endocrine therapy remains the mainstay of treatment for ER-positive, HER2-negative breast cancer, tumor progression and disease recurrence limit the utility of current standards of care. While existing therapies may allow for a prolonged progre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c529d90a848e92107a02aeb1d5c11f29
https://pubmed.ncbi.nlm.nih.gov/36077830
https://pubmed.ncbi.nlm.nih.gov/36077830
The HMGCR Inhibitor Fluvastatin Induces Apoptosis and Autophagy in Primary and Neoplastic Mast Cells
Publikováno v:
The Journal of Immunology. 202:54.12-54.12
Mast cell hyperplasia is noted in many inflammatory and allergic diseases. Mast cells can also generate a subtype of acute myelogenous leukemia. Understanding and treating mast cell hyperplasia and leukemia could be beneficial to both inflammatory an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acd8dac67cbbb23adc70fb0438c63444
https://doi.org/10.4049/jimmunol.202.supp.54.12
https://doi.org/10.4049/jimmunol.202.supp.54.12